{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:32:25Z","timestamp":1782235945881,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T00:00:00Z","timestamp":1552089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T00:00:00Z","timestamp":1552089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40121-019-0239-0","type":"journal-article","created":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T05:10:28Z","timestamp":1552108228000},"page":"155-170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Teaching an Old Class New Tricks: A Novel Semi-Synthetic Aminoglycoside, Plazomicin"],"prefix":"10.1007","volume":"8","author":[{"given":"Jacinda C.","family":"Abdul-Mutakabbir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razieh","family":"Kebriaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C. J.","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,9]]},"reference":[{"issue":"2","key":"239_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40121-017-0149-y","volume":"6","author":"E Wenzler","year":"2017","unstructured":"Wenzler E, Goff DA, Humphries R, Goldstein EJ. Anticipating the unpredictable: a review of antimicrobial stewardship and Acinetobacter infections. Infect Dis Ther. 2017;6(2):149\u201372.","journal-title":"Infect Dis Ther"},{"issue":"suppl_1","key":"239_CR2","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1093\/cid\/ciw829","volume":"64","author":"Y Doi","year":"2017","unstructured":"Doi Y, Bonomo RA, Hooper DC, Kaye KS, Johnson JR, Clancy CJ, et al. Gram-negative bacterial infections: research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017;64(suppl_1):S30\u20135.","journal-title":"Clin Infect Dis."},{"issue":"6","key":"239_CR3","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1086\/520991","volume":"45","author":"GM Eliopoulos","year":"2007","unstructured":"Eliopoulos GM, Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis. 2007;45(6):753\u201360.","journal-title":"Clin Infect Dis."},{"issue":"1","key":"239_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/phar.2203","volume":"39","author":"KM Shaeer","year":"2019","unstructured":"Shaeer KM, Zmarlicka MT, Chahine EB, Piccicacco N, Cho JC. Plazomicin: a next-generation aminoglycoside. Pharmacotherapy. 2019;39(1):77\u201393.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"239_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1128\/AAC.43.4.727","volume":"43","author":"MP Mingeot-Leclercq","year":"1999","unstructured":"Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother. 1999;43(4):727\u201337.","journal-title":"Antimicrob Agents Chemother."},{"issue":"6","key":"239_CR6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ijantimicag.2009.07.013","volume":"34","author":"SP Hawser","year":"2009","unstructured":"Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005\u20132007: results from the SMART study. Int J Antimicrob Agents. 2009;34(6):585\u20138.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"239_CR7","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1021\/acsinfecdis.8b00001","volume":"4","author":"G Cox","year":"2018","unstructured":"Cox G, Ejim L, Stogios PJ, Koteva K, Bordeleau E, Evdokimova E, Sieron AO, Savchenko A, Serio AW, Krause KM, Wright GD. Plazomicin retains antibiotic activity against most aminoglycoside modifying enzymes. ACS Infect Dis. 2018;4(6):980\u20137.","journal-title":"ACS Infect Dis."},{"issue":"5","key":"239_CR8","doi-asserted-by":"publisher","first-page":"742","DOI":"10.7164\/antibiotics.45.742","volume":"45","author":"Y Kimura","year":"1992","unstructured":"Kimura Y, Matsunaga H, Vaara M. Polymyxin B octapeptide and polymyxin B heptapeptide are potent outer membrane permeability-increasing agents. J Antibiot (Tokyo). 1992;45(5):742\u20139.","journal-title":"J Antibiot (Tokyo)"},{"issue":"1","key":"239_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/jac\/dkq408","volume":"66","author":"DM Livermore","year":"2010","unstructured":"Livermore DM, Mushtaq S, Warner M, Zhang JC, Maharjan S, Doumith M, Woodford N. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother. 2010;66(1):48\u201353.","journal-title":"J Antimicrob Chemother."},{"issue":"3","key":"239_CR10","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1099\/00221287-138-3-551","volume":"138","author":"HJ Busse","year":"1992","unstructured":"Busse HJ, W\u00f6stmann C, Barker EP. The bactericidal action of streptomycin: membrane permeabilization caused by the insertion of mistranslated proteins into the cytoplasmic membrane of Escherichia coli and subsequent caging of the antibiotic inside the cells due to degradation of these proteins. J Gen Microbiol. 1992;138(3):551\u201361.","journal-title":"J Gen Microbiol"},{"issue":"11","key":"239_CR11","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1128\/AAC.00572-10","volume":"54","author":"JB Aggen","year":"2010","unstructured":"Aggen JB, Armstrong ES, Goldblum AA, Dozzo P, Linsell MS, Gliedt MJ, Hildebrandt DJ, Feeney LA, Kubo A, Matias RD, Lopez S. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother. 2010;54(11):4636\u201342.","journal-title":"Antimicrob Agents Chemother."},{"issue":"8","key":"239_CR12","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.1128\/AAC.00099-14","volume":"58","author":"Reem Almaghrabi","year":"2014","unstructured":"Almaghrabi R, Clancy CJ, Doi Y, Hao B, Chen L, Shields RK, Press EG, Iovine NM, Townsend BM,\nWagener MM, Kreiswirth B. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in\naminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob Agents Chemother. 2014;58(8):4443-51.","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"8","key":"239_CR13","doi-asserted-by":"publisher","first-page":"e00313","DOI":"10.1128\/AAC.00313-18","volume":"62","author":"M Castanheira","year":"2018","unstructured":"Castanheira M, Davis AP, Mendes RE, Serio AW, Krause KM, Flamm RK. In vitro activity of plazomicin against Gram-negative and Gram-positive isolates collected from US hospitals and comparative activities of aminoglycosides against carbapenem-resistant Enterobacteriaceae and isolates carrying carbapenemase genes. Antimicrob Agents Chemother. 2018;62(8):e00313\u20138.","journal-title":"Antimicrob Agents Chemother."},{"issue":"12","key":"239_CR14","first-page":"3346","volume":"73","author":"M Castanheira","year":"2018","unstructured":"Castanheira M, Deshpande LM, Woosley LN, Serio AW, Krause KM, Flamm RK. Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms. J Antimicrob Chemother. 2018;73(12):3346\u201354.","journal-title":"J Antimicrob Chemother."},{"issue":"4","key":"239_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1179\/1973947812Y.0000000015","volume":"24","author":"I Galani","year":"2012","unstructured":"Galani I, Souli M, Daikos GL, Chrysouli Z, Poulakou G, Psichogiou M, et al. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J Chemother. 2012;24(4):191\u20134.","journal-title":"J Chemother."},{"issue":"2","key":"239_CR16","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/jac\/dkq459","volume":"66","author":"D Landman","year":"2010","unstructured":"Landman D, Kelly P, B\u00e4cker M, Babu E, Shah N, Bratu S, Quale J. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J Antimicrob Chemother. 2010;66(2):332\u20134.","journal-title":"J Antimicrob Chemother."},{"issue":"4","key":"239_CR17","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1128\/AAC.47.4.1371-1375.2003","volume":"47","author":"D Hocquet","year":"2003","unstructured":"Hocquet D, Vogne C, El Garch F, Vejux A, Gotoh N, Lee A, et al. MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother. 2003;47(4):1371\u20135.","journal-title":"Antimicrob Agents Chemother."},{"issue":"10","key":"239_CR18","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1128\/AAC.47.10.3202-3207.2003","volume":"47","author":"ML Sobel","year":"2003","unstructured":"Sobel ML, McKay GA, Poole K. Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother. 2003;47(10):3202\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"239_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.12.005","author":"A Walkty","year":"2018","unstructured":"Walkty A, Karlowsky JA, Baxter MR, Adam HJ, Boyd D, Bharat A, Mulvey MR, Charles M, Bergevin M, Zhanel GG. Frequency of 16S ribosomal RNA methyltransferase detection among Escherichia coli and Klebsiella pneumoniae clinical isolates obtained from patients in Canadian hospitals (CANWARD, 2013\u20132017). Diagn Microbiol Infect Dis. 2018. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.12.005.","journal-title":"Diagn Microbiol Infect Dis."},{"issue":"suppl A","key":"239_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/jac\/36.suppl_A.19","volume":"36","author":"D Sirot","year":"1995","unstructured":"Sirot D. Extended-spectrum plasmid-mediated \u03b2-lactamases. J Antimicrob Chemother. 1995;36(suppl A):19\u201334.","journal-title":"J Antimicrob Chemother."},{"key":"239_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/625170","author":"RH Dhillon","year":"2012","unstructured":"Dhillon RH, Clark J. ESBLs: a clear and present danger? Critical care research and practice. 2012. https:\/\/doi.org\/10.1155\/2012\/625170.","journal-title":"Critical care research and practice."},{"issue":"4","key":"239_CR22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.diagmicrobio.2018.07.006","volume":"92","author":"M Thwaites","year":"2018","unstructured":"Thwaites M, Hall D, Stoneburner A, Shinabarger D, Serio AW, Krause KM, et al. Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae. Diagn Microbiol Infect Dis. 2018;92(4):338\u201345.","journal-title":"Diagn Microbiol Infect Dis."},{"issue":"10","key":"239_CR23","doi-asserted-by":"publisher","first-page":"5959","DOI":"10.1128\/AAC.00873-15","volume":"59","author":"C Garcia-Salguero","year":"2015","unstructured":"Garcia-Salguero C, Rodriguez-Avial I, Picazo JJ, Culebras E. Can plazomicin alone or in combination be a therapeutic option against carbapenem-resistant Acinetobacter baumannii? Antimicrob Agents Chemother. 2015;59(10):5959\u201366.","journal-title":"Antimicrob Agents Chemother."},{"issue":"12","key":"239_CR24","doi-asserted-by":"publisher","first-page":"5874","DOI":"10.1128\/AAC.00624-11","volume":"55","author":"RT Cass","year":"2011","unstructured":"Cass RT, Brooks CD, Havrilla NA, Tack KJ, Borin MT, Young D, et al. Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects. Antimicrob Agents Chemother. 2011;55(12):5874\u201380.","journal-title":"Antimicrob Agents Chemother."},{"issue":"suppl_1","key":"239_CR25","doi-asserted-by":"publisher","first-page":"S470","DOI":"10.1093\/ofid\/ofx163.1202","volume":"4","author":"Kamilia Abdelraouf","year":"2017","unstructured":"Abdelraouf K, Kim A, Krause KM, Nicolau DP. Assessment of the In Vivo Efficacy of Plazomicin (PLZ) Alone or in Combination with Meropenem (MEM) or Tigecycline (TGC) against Enterobacteriaceae (EB) Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent (I+) Murine Septicemia Model. In: Open forum infectious diseases 2017 Oct 4 (Vol. 4, No. suppl_1, pp. S470\u2013S470). New York: Oxford University Press.","journal-title":"Open Forum Infectious Diseases"},{"issue":"4","key":"239_CR26","doi-asserted-by":"publisher","first-page":"e01989-17","DOI":"10.1128\/AAC.01989-17","volume":"62","author":"LE Connolly","year":"2018","unstructured":"Connolly LE, Riddle V, Cebrik D, Armstrong ES, Miller LG. A multicenter, randomized, double-blind, phase 2 study of the efficacy and safety of plazomicin compared with levofloxacin in the treatment of complicated urinary tract infection and acute pyelonephritis. Antimicrob Agents Chemother. 2018;62(4):e01989-17.","journal-title":"Antimicrob Agents Chemother."},{"key":"239_CR27","doi-asserted-by":"crossref","unstructured":"McKinnell JA CL, Pushkin R, Jubb AM, O\u2019Keeffe B, Serio AW, Smith A, Gall J, Riddle V, Krause KM, Pogue JM. Improved outcomes with plazomicin (PLZ) compared with colistin (CST) in patients with bloodstream infections (BSI) caused by carbapenem-resistant Enterobacteriaceae (CRE): results from the CARE study. In: Open Forum Infectious Diseases 2017 Oct 4;Vol. 4, No. suppl_1, pp. S531\u2013S531. New York: Oxford University Press.","DOI":"10.1093\/ofid\/ofx163.1383"},{"issue":"12","key":"239_CR28","doi-asserted-by":"publisher","first-page":"e01128-18","DOI":"10.1128\/AAC.01128-18","volume":"62","author":"AS Komirenko","year":"2018","unstructured":"Komirenko AS, Riddle V, Gibbons JA, Van Wart S, Seroogy JD. A phase 1 study to assess the pharmacokinetics of intravenous plazomicin in adult subjects with varying degrees of renal function. Antimicrob Agents Chemother. 2018;62(12):e01128-18.","journal-title":"Antimicrob Agents Chemother."},{"issue":"8","key":"239_CR29","doi-asserted-by":"publisher","first-page":"e00236-18","DOI":"10.1128\/AAC.00236-18","volume":"62","author":"M Thwaites","year":"2018","unstructured":"Thwaites M, Hall D, Shinabarger D, Serio AW, Krause KM, Marra A, Pillar C. Evaluation of the bactericidal activity of plazomicin and comparators against multidrug-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2018;62(8):e00236-18.","journal-title":"Antimicrob Agents Chemother."},{"key":"239_CR30","unstructured":"US Food and Drug Administration briefing document. Plazomicin sulfate injection. Document prepared for the meeting of the Antimicrobial Drugs Advisory Committee (AMDAC). 2 May 2018. https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM606039.pdf. Accessed 15 Oct 2018."},{"key":"239_CR31","unstructured":"Shrimant M. NDA 210303 Clinical review plazomicin injection (Zemdri\u2122). Center for Drug Evaluation and Research. US Food and Drug Administration. 13 June 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210303Orig1s000MedR.pdf Accessed 15 Oct 2018."},{"key":"239_CR32","unstructured":"Shurland SM. NDA 210303 Clinical microbiology review plazomicin injection (Zemdri\u2122). Center for Drug Evaluation and Research. US Food and Drug Administration. 17 May 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210303Orig1s000MicroR.pdf Accessed 15 Oct 2018."},{"key":"239_CR33","unstructured":"Nambiar S, Cox E. NDA 210303 Summary review plazomicin injection (Zemdri\u2122) . Center for Drug Evaluation and Research. US Food and Drug Administration. 25 June 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210303Orig1s000SumR.pdf. Accessed15 Oct 2018."},{"key":"239_CR34","unstructured":"Kostrub CF, Dolan DF, Altschuler RA, Baird TJ, Tapp RL, Boggs JA, Bruss JB. Ototoxic potential of ACHN-490 compared to gentamicin and amikacin in the guinea pig. In: presented at: 20th European congress of clinical microbiology and infectious diseases. Vienna, AT, 10-13 April 2010. Abstract P1249."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-019-0239-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-019-0239-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-019-0239-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:12:46Z","timestamp":1728922366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-019-0239-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,9]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["239"],"URL":"https:\/\/doi.org\/10.1007\/s40121-019-0239-0","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,9]]},"assertion":[{"value":"14 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}